Boston, MA -- (SBWIRE) -- 03/21/2014 -- Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. It can result in anoxia, the complete deprivation of oxygen and infarction, and even tissue death. Twelve million people worldwide are killed every year by cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral infarction, myocardial infarction, coronary heart disease and arteriosclerosis. It equals to nearly one-fourth of global death toll. Incidence of cardiovascular diseases keeps rising in China. The number of cardiovascular diseases patients in China now is estimated to be 290 million with 2 patients among 10 adults. It is estimated that about 3.5 million people die of cardiovascular diseases every year in China. This number has topped all diseases and takes up 40% of total death toll.
View Full Report Details and Table of Contents
Heparin drugs are widely used in hemodialysis and various surgical operations. Because low-molecular-weight heparin preparation is more widely used in clinical practice than unfractionated heparin preparation, the later is gradually being replaced by the former. Low-molecular-weight heparin preparation took up over 85% of the global heparin market from 2005 to 2010. Enoxaparin sodium is an important variety of low-molecular-weight heparin preparations, which is originally developed by Aventis (later merged with Sanofi). It was approved to the market in 1993 with the trade name "Lovenox". The active ingredient of the medication is a natural derivative of certain type of sugar molecule. Enoxaparin sodium injection produced by Sanofi was approved to the U.S. market in October 2004 by the FDA. It entered Chinese market early 2005.
Enoxaparin sodium can not only prevent DVT (deep vein thrombosis) and pulmonary embolism but also treat venous thrombosis. It can prevent thrombus in extracorporeal circulation during hemodialysis, and treat unstable angina and non-Q-wave myocardial infarction. Enoxaparin sodium generic drugs produced by Sandoz and Amphastar Pharm have gone on the market in succession since 2010, leading to a dramatic sales drop of similar products produced by Sanofi. The downstream market is thus reorganized. Global sales revenue of Lovenox in 2012 is approximately USD 2.5 billion, which decreased 10.3% YOY.
Four manufacturers in China have received production approval of enoxaparin sodium injection by early 2014. According to CRI's market investigation, products of Sanofi and its related enterprises occupy most market share in Chinese sample hospitals, followed by Hangzhou Jiuyuan Gene Engineering Co., Ltd.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Investigation Report on China Montelukast Market, 2009-2018
- Non-Small Cell Lung Cancer - Pipeline Review, H2 2013
- Investigation Report on China Duloxetine Market, 2009-2018
- Investigation Report on China Budesonide Market, 2009-2018
- Investigation Report on China Bevacizumab Market, 2009-2018
- Investigation Report on China Insulin Glargine Market, 2009-2018
- Investigation Report on China Rituximab Market, 2009-2018
- Investigation Report on China Quetiapine Market, 2009-2018
- Investigation Report on China Tacrolimus Market, 2009-2018
- Investigation Report on China Telmisartan Market, 2009-2018